UBT251
Novo Nordisk / United Laboratories
Once-weekly triple agonist in Phase 3 obesity development in China.
Selected study results
China Phase 2 obesity studyLeast-squares mean change in body weight at week 24Body weight decreased 19.7% · 24 weeks · Phase 2
Least-squares mean change in body weight at week 24 · 24 weeks
Study focus: Weight management
Adults with overweight or obesity in China · Once-weekly injection; the published range spans UBT251 dose groups and this summary does not assign the maximum to a specific dose · Trial N=205 · Peer-reviewed, randomized, double-blind, placebo-controlled Phase 2 report; week-24 least-squares mean percentage change. Results & methods ↗
A 24-week Phase 2 trial in adults with overweight or obesity in China. The published range spans dose groups; the maximum is not assigned to a specific dose in this summary. Long-term and global obesity-study results remain pending.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Peer-reviewed China Phase 2 obesity results published: 24-week body-weight change ranged from 13.6% to 19.7% across UBT251 groups versus 2.0% with placebo. The China Phase 3 obesity trial started September 4, 2026.
Next: China Phase 3 and global obesity study results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
China Phase 3 obesity study
Weight managementPlacebo-controlled study in China with estimated enrollment of 600 adults. The primary outcome is percentage change in body weight at week 52.
Phase 2 studies2 records
China obesity study
Weight managementOverweight/obesity in China; randomized, double-blind, placebo-controlled; peer-reviewed results published in Cell Metabolism.
Global obesity study
Weight managementGlobal Phase 2 obesity protocol; registry recruiting. Separate from the published China Phase 2 trial.
